Bone Mineral Density in Postmenopausal Breast Cancer Survivors
- 1 June 2001
- journal article
- Published by Wiley in Journal of the American Academy of Nurse Practitioners
- Vol. 13 (6) , 276-284
- https://doi.org/10.1111/j.1745-7599.2001.tb00035.x
Abstract
Purpose The overall purpose of this longitudinal 18‐month study was to test the feasibility and effectiveness of a multicomponent intervention for prevention and treatment of osteoporosis. The purpose of this article is to describe the baseline bone mineral density (BMD) findings for 30 postmenopausal women and to compare these BMD findings to time since menopause, body mass index, and tamoxifen use. Data Sources Baseline data of BMD findings for 30 post‐menopausal women, who have had a variety of treatments including surgery, adjuvant chemotherapy and or tamoxifen, and are enrolled in the 18‐month longitudinal study. A demographic questionnaire and a three day dietary record were used to collect baseline data. Conclusions Eighty percent of the women with breast cancer history had abnormal BMDs at baseline (t‐scores below ‐1.00 SD). Thinner women showed a greater risk for accelerated trabecular bone loss at the spine and hip. Implications for Practice These findings suggest the need for early BMD assessments and for aggressive health promotion intervention strategies that include a multifaceted protocol of drug therapy for bone remodeling, 1500 mg of daily calcium, 400 IU vitamin D and a strength weight training program that is implemented immediately following chemotherapy treatment and menopause in this high risk population of women.Keywords
This publication has 28 references indexed in Scilit:
- Treatment of Established Postmenopausal Osteoporosis with Raloxifene: A Randomized TrialJournal of Bone and Mineral Research, 1998
- Bone Loss, Physical Activity, and Weight Change in Elderly Women: The Dubbo Osteoporosis Epidemiology StudyJournal of Bone and Mineral Research, 1998
- Effects of Raloxifene on Bone Mineral Density, Serum Cholesterol Concentrations, and Uterine Endometrium in Postmenopausal WomenNew England Journal of Medicine, 1997
- Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosisBone, 1996
- Does long-term administration of tamoxifen affect bone mineral density?European Journal Of Cancer, 1993
- Oestrogenic effects of adjuvant tamoxifen in postmenopausal breast cancerEuropean Journal Of Cancer, 1993
- Current methods and recent advances in the diagnosis of osteoporosisArthritis & Rheumatism, 1993
- Nutritional Factors in OsteoporosisAnnual Review of Nutrition, 1993
- Bone mineral density (BMD) in patients with lymphoma: The effects of chemotherapy, intermittent corticosteroids and premature menopauseHematological Oncology, 1992
- Assessment of the risk of post‐menopausal osteoporosis using clinical factorsClinical Endocrinology, 1992